X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (220) 220
oncology (156) 156
female (131) 131
male (129) 129
middle aged (123) 123
adult (114) 114
aged (108) 108
24-hour infusion (84) 84
infusions, intravenous (75) 75
fluorouracil - administration & dosage (72) 72
antineoplastic combined chemotherapy protocols - therapeutic use (69) 69
weekly 24-hour infusion (67) 67
chemotherapy (66) 66
leucovorin - administration & dosage (60) 60
pharmacology & pharmacy (60) 60
drug administration schedule (57) 57
treatment outcome (56) 56
colorectal neoplasms - drug therapy (55) 55
fluorouracil (55) 55
5-fluorouracil (50) 50
index medicus (50) 50
leucovorin (50) 50
carcinoma (44) 44
antineoplastic combined chemotherapy protocols - adverse effects (43) 43
folinic acid (42) 42
cancer (41) 41
24-hour continuous-infusion (37) 37
pharmacokinetics (35) 35
colorectal cancer (33) 33
colorectal neoplasms - pathology (32) 32
dose-response relationship, drug (31) 31
camptothecin - analogs & derivatives (29) 29
fluorouracil - adverse effects (29) 29
neoplasms - drug therapy (29) 29
phase-ii (28) 28
trial (28) 28
oxaliplatin (27) 27
randomized trial (26) 26
1st-line treatment (25) 25
animals (25) 25
antineoplastic agents - therapeutic use (25) 25
irinotecan (25) 25
paclitaxel (25) 25
aged, 80 and over (24) 24
high-dose 5-fluorouracil (24) 24
survival analysis (24) 24
antineoplastic combined chemotherapy protocols - administration & dosage (23) 23
cisplatin (23) 23
neoplasm metastasis (23) 23
advanced colorectal-cancer (22) 22
topotecan (22) 22
leucovorin - adverse effects (21) 21
survival rate (21) 21
colorectal neoplasms - mortality (20) 20
gastroenterology & hepatology (20) 20
randomized-trial (20) 20
solid tumors (20) 20
antimetabolites, antineoplastic - administration & dosage (19) 19
antineoplastic agents - adverse effects (19) 19
phase-i (19) 19
antineoplastic agents - administration & dosage (18) 18
cell lung-cancer (18) 18
fluorouracil - therapeutic use (18) 18
adenocarcinoma - drug therapy (17) 17
deoxycytidine - analogs & derivatives (17) 17
medicine & public health (17) 17
phase-ii trial (17) 17
therapy (17) 17
maximum tolerated dose (16) 16
neoplasm staging (16) 16
organoplatinum compounds - administration & dosage (16) 16
antineoplastic agents - pharmacokinetics (15) 15
camptothecin - administration & dosage (15) 15
child (15) 15
cisplatin - administration & dosage (15) 15
colony-stimulating factor (15) 15
disease-free survival (15) 15
paclitaxel - administration & dosage (15) 15
pharmacodynamics (15) 15
phase-i trial (15) 15
breast-cancer (14) 14
clinical trials as topic (14) 14
deoxycytidine - administration & dosage (14) 14
fluorouracil plus leucovorin (14) 14
high-dose leucovorin (14) 14
neutropenia - chemically induced (14) 14
paclitaxel - adverse effects (14) 14
adolescent (13) 13
antineoplastic agents, phytogenic - therapeutic use (13) 13
gemcitabine (13) 13
quality-of-life (13) 13
camptothecin - therapeutic use (12) 12
drug therapy (12) 12
medicine, general & internal (12) 12
surgery (12) 12
taxol (12) 12
time factors (12) 12
5-fu (11) 11
biochemical modulation (11) 11
camptothecin (11) 11
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (263) 263
German (11) 11
Spanish (2) 2
French (1) 1
Italian (1) 1
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Zhao, DH and Chen, J and Chu, MM and Wang, JS
ONCOTARGETS AND THERAPY, ISSN 1178-6930, 2019, Volume 12, pp. 4859 - 4868
Background: The present standard dose of gemcitabine (Gem), a pyrimidine antimetabolite, is 1,000-1,250 mg/m(2), and the infusion time is 30 min However,... 
CARBOPLATIN | 24-HOUR INFUSION | SOLID TUMORS | PRIMARY CHEMOTHERAPY | COMBINATION | PREVIOUSLY UNTREATED PATIENTS | prolonged infusion | BREAST-CANCER | PHASE-II TRIAL | CISPLATIN | ONCOLOGY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | pharmacokinetics | gemcitabine | low dose | POOR PERFORMANCE STATUS
Journal Article
Oncology Reports, ISSN 1021-335X, 08/2018, Volume 40, Issue 2, pp. 803 - 812
Journal Article
The Lancet, ISSN 0140-6736, 1998, Volume 352, Issue 9138, pp. 1407 - 1412
Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 02/2012, Volume 23, Issue 2, pp. 230 - 238
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 03/2011, Volume 22, Issue 3, pp. 290 - 298
The primary aim of the high-dose 5-fluorouracil (5-FU) and leucovorin (LV; HDFL48) phase I study was to determine the maximum tolerated dose and dose-limiting... 
5-fluorouracil | pharmacokinetics | phase I | colorectal cancer | 48-h infusion | bone marrow drug level | THYMIDYLATE SYNTHASE | WEEKLY 24-HOUR INFUSION | RANDOMIZED-TRIAL | OXALIPLATIN | ENCEPHALOPATHY | FLUOROURACIL BOLUS | THERAPY | ONCOLOGY | PLUS ORAL LEUCOVORIN | IRINOTECAN | PHARMACOLOGY & PHARMACY | SCHEDULES
Journal Article
Oncology, ISSN 0030-2414, 01/2003, Volume 64, Issue 2, pp. 131 - 138
Journal Article
Journal Article
JOURNAL OF CLINICAL PHARMACOLOGY, ISSN 0091-2700, 03/2010, Volume 50, Issue 3, pp. 268 - 275
Topotecan pharmacokinetics at higher infusion rates (4 mg/m(2) over 30 minutes) have not been studied. The authors report a pharmacokinetics and safety study... 
SOLID TUMORS | 24-HOUR CONTINUOUS-INFUSION | LONG-TERM SURVIVAL | PHARMACODYNAMICS | weekly | EPITHELIAL OVARIAN-CANCER | CHEMOTHERAPY | PACLITAXEL | intravenous | RECURRENT | safety | pharmacokinetics | PHARMACOLOGY & PHARMACY | INHIBITOR | CARCINOMA | topotecan
Journal Article
Lung Cancer, ISSN 0169-5002, 2007, Volume 60, Issue 2, pp. 208 - 214
Journal Article